NetWellness is a global, community service providing quality, unbiased health information from our partner university faculty. NetWellness is commercial-free and does not accept advertising.
Wednesday, July 23, 2014
Colon cancer patient using vectibix
What is their survival rate after eleven months of chemo and no other options but vextibix.
It is difficult to answer without knowing more details. But in patients who failed multiple therapies and got vectibix only, average survival is less than 6 months.
Malek Safa, MD
Assistant Professor of Medicine
College of Medicine
University of Cincinnati